Lista de obras -

A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study

artículo científico publicado en 2015

Assessing the quality of studies on the diagnostic accuracy of tumor markers ⬇️

artículo científico publicado en 2014

Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example

artículo científico publicado en 2016

Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium

artículo científico publicado en 2010

Bladder cancer--the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov

artículo científico publicado en 2013

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

artículo científico publicado en 2005

CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.

artículo científico publicado en 2017

Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma

artículo científico publicado en 2015

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

artículo científico

Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma.

artículo científico publicado en 2014

Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank.

artículo científico publicado en 2005

Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma

artículo científico publicado en 2020

Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.

artículo científico publicado en 2014

Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012.

artículo científico publicado en 2014

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

artículo científico publicado en 2013

Efficacy and safety of TachoSil as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study

artículo científico publicado en 2007

Environmental exposure, chlorinated drinking water, and bladder cancer

artículo científico publicado en 2003

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study ⬇️

artículo científico publicado el 25 de febrero de 2013

Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study

artículo científico publicado en 2015

Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma.

artículo científico publicado en 2015

Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations

artículo científico publicado en 2016

Functional analyses and prognostic significance of SFRP1 expression in bladder cancer

artículo científico publicado en 2015

Guidelines for development of diagnostic markers in bladder cancer

artículo científico publicado en 2008

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer

artículo científico publicado en 2004

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis

artículo científico publicado en 2017

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study

artículo científico publicado en 2014

Low-grade Ta (noninvasive) urothelial carcinoma of the bladder

artículo científico publicado en 2005

Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines

artículo científico publicado en 2016

Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice

artículo científico publicado en 2014

New concepts of biobanks--strategic chance for uro-oncology

artículo científico publicado en 2010

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

artículo científico publicado en 2005

Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk

artículo científico publicado en 2013

SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.

artículo científico publicado en 2013

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

artículo científico

Statistical consideration for clinical biomarker research in bladder cancer

artículo científico publicado en 2010

Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry

artículo científico publicado en 2016

Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer

artículo científico publicado en 2013

Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany

artículo científico publicado en 2015

The International Bladder Cancer Bank: proposal for a new study concept

artículo científico publicado en 2004

The International Bladder Cancer Network

artículo científico publicado en 2010

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape

artículo científico

Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial

artículo científico publicado en 2020

Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice

artículo científico publicado en 2014

Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience

artículo científico publicado en 2015

Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.

artículo científico publicado en 2017

p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer

artículo científico

Lista de obras de

A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study

Assessing the quality of studies on the diagnostic accuracy of tumor markers ⬇️

Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example

Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium

Bladder cancer--the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.

Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma.

Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank.

Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma

Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.

Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012.

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

Efficacy and safety of TachoSil as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study

Environmental exposure, chlorinated drinking water, and bladder cancer

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study ⬇️

Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study

Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma.

Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations

Functional analyses and prognostic significance of SFRP1 expression in bladder cancer

Guidelines for development of diagnostic markers in bladder cancer

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study

Low-grade Ta (noninvasive) urothelial carcinoma of the bladder

Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines

Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice

New concepts of biobanks--strategic chance for uro-oncology

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk

SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Statistical consideration for clinical biomarker research in bladder cancer

Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry

Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer

Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany

The International Bladder Cancer Bank: proposal for a new study concept

The International Bladder Cancer Network

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape

Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial

Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice

Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience

Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.

p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer